CLINICAL TRIAL
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Add like
Add dislike
Add to saved papers

The efficacy of enrofloxacin in-feed medication, by applying different programmes for the control of post weaning diarrhoea syndrome of piglets.

Post weaning diarrhoea syndrome (PWDS) in piglets is caused mainly by enterotoxigenic Escherichia (E.) coli (ETEC) strains. Six different in-feed usage programmes of enrofloxacin (ENR/Baytril; I.E.R. 2.5%) were tested for their efficacy on the control of post weaning colibacillosis in piglets, using seven groups with totally 336 weaned piglets for a 28 day period. One group (negative control) was offered feed free of antimicrobials, three groups were offered feed medicated with 50 ppm of ENR starting on weaning day for 5, 7 and 10 days respectively, three groups were offered feed medicated with 50 ppm of ENR starting 7 days post weaning for 5, 7 and 10 days respectively, and were compared with regard to the appearance of clinical signs, mortality, weight gain and feed conversion. The results showed that all ENR treatments reduced the incidence and severity of diarrhoea. Mortality was similar in all ENR treatments, but in the groups where the ENR was added for 10 days immediately after weaning and/or 7 days post weaning for 7 and 10 days respectively was lower compared to the negative control group (P < 0.05). The evaluation of the weight gain data, as well as feed conversion ratio indicated that the six treated groups performed remarkably better than the control group (P < 0.05). No ETEC were detected on days 21 and 28 in all ENR groups contrary to the untreated control. It was concluded that a strategic medication initiated 7 days post weaning with 50 ppm of ENR and only for 7 and 10 days period of time is a useful tool in controlling PWDS due to ETEC.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app